KMT2D and diffuse large B-cell lymphoma: According to the Kaplan-Meier analysis, the overexpression of KMT2D and MYC were both inferior prognostic factors in EBV+ DLBCL patients, with an mOS of 17 months vs. 29 months (P = 0.012) and 16 months vs. 29 months (P = 0.001), respectively.